Logo

Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Initiative

Share this
Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Initiative

Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Initiative

Shots:

  • The government of Saskatchewan will implement a switching or transitioning policy to expand the use of biosimilar medicines under its public drug programs and reinvest the savings to support patient access to public drug coverage and new drug benefits
  • Saskatchewan joined 5 provinces and 1 territory in implementing a biosimilar switching policy, allowing for reference products to be switched out for biosimilars and lowering drug costs for the province’s public health plan
  • Patients who are covered by the Saskatchewan Drug Plan and received biological drugs will have to switch to a biosimilar version of their medicine by April 2023 to treat conditions incl. arthritis, diabetes, IBD & psoriasis

Ref: Saskatchewan | Image: Saskatchewan

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions